Clinical TrialOct 26, 2026, 07:36 AM
Immatics Presents Positive Clinical Data for IMA402 and IMA203CD8 at ESMO
AI Summary
Immatics N.V. presented updated clinical trial data for its IMA402 PRAME bispecific and IMA203CD8 PRAME cell therapy at the 2026 ESMO Annual Meeting. IMA402 demonstrated encouraging anti-tumor activity and a favorable safety profile, with a 32% cORR in PRAME-high melanoma patients. IMA203CD8 showed deep and durable anti-tumor activity across multiple tumor types, with a 55% cORR in heavily pretreated gynecologic cancer patients. The company also provided an update on anzu-cel (IMA203), which is progressing in its Phase 3 SUPRAME trial.
Key Highlights
- IMA402 PRAME bispecific achieved 32% cORR in PRAME-high melanoma patients with 12.5 months median DOR and 91% 1-year OS.
- IMA203CD8 PRAME cell therapy showed 55% cORR in heavily pretreated gynecologic cancer patients with 8.4 months median DOR.
- IMA402 demonstrated 25% cORR across all indications and 63% DCR in a heavily pretreated patient population.
- IMA203CD8 showed 41% cORR and 82% DCR across multiple advanced solid tumor types.
- Anzu-cel (IMA203) Phase 3 SUPRAME trial in advanced melanoma is ongoing, with topline data expected in 1H 2027.
- Immatics is advancing its PRAME franchise with multiple clinical-stage programs in cell therapies and bispecifics.
Price Impact
More from IMTX